On Feb. 7, the U.S. Food and Drug Administration announced that drug interactions between the hepatitis C virus protease inhibitor Victrelis (boceprevir) and certain ritonavir-boosted human immunodeficiency virus protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these medications when they are used in combination. Read . . .
The U.S. Food and Drug Administration has updated the boxed warning tumor necrosis factor-alpha blockers to include the risk of infection from Legionella and Listeria. Read more . . .
The U.S. Food and Drug Administration has approved Benlysta (belimumab) for treatment of lupus. The FDA last approved a drug for lupus in 1955. Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm246489.htm . . .
The U.S. Food and Drug Administration announced that new safety information has been added to the label for the HIV antiviral drug Invirase (saquinavir). The warning describes potentially life-threatening cardiovascular side effects the drug is used with Norvir (ritonavir). Read more at http://www.fda.gov/NewsEvents/Newsroom . . .
Think you know all about rheumatoid arthritis? Think again. Misunderstandings about the disease abound, even among healthcare professionals.
A study presented at the American Society of Clinical Oncology June meeting found that removing additional axillary lymph nodes to look for breast cancer in women with limited disease spread in the sentinel node does not improve survival. Read more about studies reporting progress against breast cancer at http://www . . .